In other studies, JAK2 V617F mutations were found to be unlikely to play a significant role in the pathophysiology of MDS with or without secondary fibrosis and it was suggested that strict criteria should be applied to exclude the more likely diagnosis of MPN in transformation when JAK2 V617F is detected in patients with dysplasia and myelofibrosis [22]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.